Bone morphogenetic protein pathway responses and alterations of osteogenesis in metastatic prostate cancers.

ABSTRACT:

Background

Prostate cancer is a common cancer in men that annually results in more than 33 000 US deaths. Mortality from prostate cancer is largely from metastatic disease, reflecting on the great strides in the last century of treatments in care for the localized disease. Metastatic castrate resistant prostate cancer (mCRPC) will commonly travel to the bone, creating unique bone pathology that requires nuanced treatments in those sites with surgical, radio and chemotherapeutic interventions. The bone morphogenetic protein (BMP) pathway has been historically studied in the capacity to regulate the osteogenic nature of new bone. New mineralized bone generation is a frequent and common observation in mCRPC and referred to as blastic bone lesions. Less common are bone destructive lesi

SUBMITTER: Provera MD 

PROVIDER: S-EPMC9940003 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature